Can an antioxidant slow vision loss? new trial tests NAC for retinitis pigmentosa

NCT ID NCT03999021

Ongoing Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study is testing the long-term safety of a high-dose antioxidant called N-Acetylcysteine (NAC) in 30 adults with retinitis pigmentosa, an inherited eye disease that causes gradual vision loss and blindness. Participants take 1800 mg of NAC twice daily for two years, with regular check-ups to monitor side effects and tolerability. The goal is to see if NAC can be safely used long-term to potentially slow the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: N-Acetylcysteine (NAC) effervescent tablets
What this could lead to: If NAC is safe and effective long-term, it could slow vision loss and delay blindness in people with retinitis pigmentosa.
What could go wrong: This is a small, early-phase safety study with only 30 participants, so it cannot prove whether NAC actually preserves vision. Side effects like nausea, vomiting, and allergic reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinitis pigmentosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINITIS PIGMENTOSA

Contacts and locations

Locations

Wilmer Eye Institute at Johns Hopkins University

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.